January 13, 2025
Formycon, Teva team up for Formycon’s biosimilar candidate aflibercept in Europe and Israel
Klinge Biopharma GmbH, the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimilar candidate to Eylea (Aflibercept),has signed a licensing agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. for the semi-exclusive commercialization of FYB203 in major parts of Europe and Israel. In parallel Formycon has signed an agreement with Teva under which Formycon will supply the finished product.